Carnegie Pharmaceuticals Llc

Carnegie Pharmaceuticals LLC specializes in unique generic and brand products with development barriers. Carnegie Pharmaceuticals has carefully invested in a team, infrastructure, and pipeline to create an organization that consistently delivers specialized pharmaceutical products made in the United States for both domestic and global distribution. Commercial products include: • Primidone tablets (Dec 2024) • E.E.S.® Granules (erythromycin ethylsuccinate for oral suspension)(Feb 2025) • E.E.S. 400® film-coated tablets (erythromycin ethylsuccinate tablets)(Feb 2025) • EryPed® 400 (erythromycin ethylsuccinate for oral suspension)(Feb 2025) • Clindamycin phosphate pledgets (Jul 2025) • Balsalazide disodium capsules (Jul 2025) • Aminocaproic acid oral suspension (Sep 2025) • Famotidine for oral suspension (Sep 2025) • Lomustine capsules (Nov 2025)